Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Docetaxel in mCRPC
NCT05348577Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started Mar 2022; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05348577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348577.